Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease PatientsCompleted
NCT06203704N/AUpdated Oct 28, 2025
Sponsor: AstraZeneca
Chronic Kidney Disease (CKD)
Bulgaria, Croatia, Hungary, Poland, Romania +2 more
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisCompleted
NCT05809934Phase 2Updated Oct 28, 2025
Sponsor: AstraZeneca
Nonalcoholic Steatohepatitis
United States, Argentina, Brazil, Chile, China +17 more
FAITH - Factor XA Inhibitor-Related InTracranial HaemorrhageCompleted
NCT06420011N/AUpdated Oct 27, 2025
Sponsor: AstraZeneca
InTracranial Haemorrhage
Argentina, Brazil, Colombia, Mexico, Qatar +2 more
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive Not Recruiting
NCT03334617Phase 2Updated Oct 27, 2025
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Austria, Canada, France, Germany +3 more
A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese ParticipantsCompleted
NCT06368440Phase 1Updated Oct 24, 2025
Sponsor: AstraZeneca
Healthy Participants
United States
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdRecruiting
NCT06533826Phase 2Updated Oct 24, 2025
Sponsor: Ana C Garrido-Castro, MD
Breast Cancer · HER2-low Breast Cancer · Metastatic Breast Cancer · HER2-negative Breast Cancer
United States
Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With AsthmaCompleted
NCT06435273Phase 2Updated Oct 23, 2025
Sponsor: AstraZeneca
Asthma
Canada, Denmark, Germany, Spain, United Kingdom
Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUSCompleted
NCT03918304N/AUpdated Oct 23, 2025
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
South Korea
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerActive Not Recruiting
NCT04397003Phase 2Updated Oct 22, 2025
Sponsor: Washington University School of Medicine
Extensive-stage Small Cell Lung Cancer
United States
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)Active Not Recruiting
NCT03401385Phase 1Updated Oct 21, 2025
Sponsor: Daiichi Sankyo Co., Ltd.
Hormone Receptor Positive Breast Cancer · Triple Negative Breast Cancer · Non-small Cell Lung Cancer
United States, Japan
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]Active Not Recruiting
NCT03529110Phase 3Updated Oct 21, 2025
Sponsor: Daiichi Sankyo
Breast Cancer
United States, Australia, Belgium, Brazil, Canada +10 more
Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and OutcomesCompleted
NCT07159295N/AUpdated Oct 21, 2025
Sponsor: AstraZeneca
Severe Asthma
Portugal
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004Completed
NCT06813781Phase 1Updated Oct 15, 2025
Sponsor: AstraZeneca
Hepatic Impairment
United States
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLCTerminated
NCT05215951Phase 2Updated Oct 15, 2025
Sponsor: AstraZeneca
Lung Cancer
China
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)Recruiting
NCT06174987Phase 3Updated Oct 15, 2025
Sponsor: Daiichi Sankyo
Advanced Cancer · Metastatic Cancer
United States, Australia, Belgium, Brazil, France +7 more
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive Not Recruiting
NCT04711252Phase 3Updated Oct 14, 2025
Sponsor: AstraZeneca
ER-Positive HER2-Negative Breast Cancer
United States, Austria, Belgium, Bulgaria, Canada +22 more
A Study of Inhaled AZD8630 in Adolescents With AsthmaCompleted
NCT07065331Phase 1Updated Oct 14, 2025
Sponsor: AstraZeneca
Asthma
United States
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy ParticipantsCompleted
NCT06948747Phase 1Updated Oct 10, 2025
Sponsor: AstraZeneca
Healthy Participants
United States
OPTIMISE-CKD Study_current Clinical Landscape in SpainCompleted
NCT06614712N/AUpdated Oct 10, 2025
Sponsor: AstraZeneca
Renal Disease
Spain
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active Not Recruiting
NCT04035486Phase 3Updated Oct 10, 2025
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Argentina, Australia, Brazil, Canada +16 more
Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of LifeCompleted
NCT05437510Phase 3Updated Oct 9, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
RSV Immunization · Healthy Volunteer
France, Germany, United Kingdom
Forxiga CKD Japan Post-Marketing Surveillance (PMS)Completed
NCT05306210N/AUpdated Oct 9, 2025
Sponsor: AstraZeneca
Chronic Kidney Disease
Japan
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid CancerActive Not Recruiting
NCT04931654Phase 1, Phase 2Updated Oct 9, 2025
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung · Gastric Cancer · Gastroesophageal Junction Cancer
United States, Canada, China, France, Georgia +5 more
Bringing Knowledge About Chronic Kidney Disease in Brazil: Filling the GapCompleted
NCT07103629N/AUpdated Oct 8, 2025
Sponsor: AstraZeneca
Renal Insufficiency, Chronic
Brazil
Safety Of DAPAGLIFLOZIN (FORXIGA) in Patient With Type 2 Diabetes Mellitus (T2dm) In Vietnam From A Post-Marketing Surveillance ProgramCompleted
NCT07210307N/AUpdated Oct 7, 2025
Sponsor: AstraZeneca
Safety Outcomes
Vietnam

Previous page Next page